WST - West Pharmaceutical Services, Inc.
NYSE
->
Healthcare
->
Medical Instruments & Supplies
Exton,
United States
Type: Equity
WST price evolution
WST
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $446.2 | $601.8 | $853.9 | |
| Short term investments | ||||
| Net receivables | $524.3 | $479.4 | $524 | $512 |
| Inventory | $401.2 | $419.2 | $429.9 | $434.7 |
| Total current assets | $1550.6 | $1483 | $1692.9 | $1936.4 |
| Long term investments | $198.2 | $202.5 | $210 | |
| Property, plant & equipment | $1710.9 | $1604 | $1545.4 | $1512.5 |
| Goodwill & intangible assets | $120.2 | $121.5 | $123.6 | |
| Total noncurrent assets | $2006.4 | $1909.4 | $1893.1 | |
| Total investments | $198.2 | $202.5 | $210 | |
| Total assets | $3675.1 | $3489.4 | $3602.3 | $3829.5 |
| Current liabilities | ||||
| Accounts payable | $224.3 | $211.7 | $240.1 | $242.4 |
| Deferred revenue | ||||
| Short long term debt | $153.2 | $151.4 | $151.7 | |
| Total current liabilities | $516.5 | $633.7 | $648.4 | $671.8 |
| Long term debt | $204.8 | $157.5 | $155.2 | $157.3 |
| Total noncurrent liabilities | $278.9 | $273.3 | $276.7 | |
| Total debt | $310.7 | $306.6 | $309 | |
| Total liabilities | $923 | $912.6 | $921.7 | $948.5 |
| Shareholders' equity | ||||
| Retained earnings | $3856.9 | $3720.9 | $3624.1 | $3523.4 |
| Other shareholder equity | -$138.6 | -$216.9 | -$192.3 | -$143.8 |
| Total shareholder equity | $2576.8 | $2680.6 | $2881 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $853.9 | $894.3 | $762.6 | $615.5 |
| Short term investments | ||||
| Net receivables | $512 | $507.4 | $489 | $385.3 |
| Inventory | $434.7 | $414.8 | $378.4 | $321.3 |
| Total current assets | $1936.4 | $1919.5 | $1742 | $1373.7 |
| Long term investments | $210 | $204.9 | $207.7 | $214.7 |
| Property, plant & equipment | $1512.5 | $1262.7 | $1126.8 | $1011.5 |
| Goodwill & intangible assets | $123.6 | $125.7 | $132.9 | $141.6 |
| Total noncurrent assets | $1893.1 | $1697.3 | $1571.8 | $1420.1 |
| Total investments | $210 | $204.9 | $207.7 | $214.7 |
| Total assets | $3829.5 | $3616.8 | $3313.8 | $2793.8 |
| Current liabilities | ||||
| Accounts payable | $242.4 | $215.4 | $232.2 | $213.1 |
| Deferred revenue | ||||
| Short long term debt | $151.7 | $18.2 | $53.5 | $12.4 |
| Total current liabilities | $671.8 | $519 | $594.1 | $503.4 |
| Long term debt | $157.3 | $206.7 | $271.8 | $313.3 |
| Total noncurrent liabilities | $276.7 | $412.9 | $384.3 | $435.9 |
| Total debt | $309 | $317.9 | $325.3 | $325.7 |
| Total liabilities | $948.5 | $931.9 | $978.4 | $939.3 |
| Shareholders' equity | ||||
| Retained earnings | $3523.4 | $2987.8 | $2456.7 | $1846.7 |
| Other shareholder equity | -$143.8 | -$184.6 | -$159.6 | -$110.6 |
| Total shareholder equity | $2881 | $2684.9 | $2335.4 | $1854.5 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $746.9 | $702.1 | $695.4 | $732 |
| Cost of revenue | $472.1 | $465.2 | $453.8 | |
| Gross Profit | $264.7 | $230 | $230.2 | $278.2 |
| Operating activities | ||||
| Research & development | $17.5 | $17.6 | $18.4 | |
| Selling, general & administrative | $83 | $86.7 | $90 | |
| Total operating expenses | $100.8 | $103.8 | $107.4 | $117.3 |
| Operating income | $126.2 | $122.8 | $160.9 | |
| Income from continuing operations | ||||
| EBIT | $134.7 | $133.3 | $172.7 | |
| Income tax expense | $32.4 | $21.9 | $16.4 | $34.5 |
| Interest expense | -$0.2 | $1.5 | $1.6 | $1.2 |
| Net income | ||||
| Net income | $136 | $111.3 | $115.3 | $137 |
| Income (for common shares) | $111.3 | $115.3 | $137 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2949.8 | $2886.9 | $2831.6 | $2146.9 |
| Cost of revenue | $1820.6 | $1750.7 | $1655.8 | $1379.1 |
| Gross Profit | $1129.2 | $1136.2 | $1175.8 | $767.8 |
| Operating activities | ||||
| Research & development | $68.4 | $58.5 | $52.8 | $46.9 |
| Selling, general & administrative | $353.4 | $316.9 | $362.8 | $302 |
| Total operating expenses | $453.2 | $402.2 | $423.5 | $360.9 |
| Operating income | $676 | $734 | $752.3 | $406.9 |
| Income from continuing operations | ||||
| EBIT | $724.7 | $708.5 | $777.2 | $426.9 |
| Income tax expense | $122.3 | $114.7 | $107.2 | $72.5 |
| Interest expense | $9 | $7.9 | $8.2 | $8.2 |
| Net income | ||||
| Net income | $593.4 | $585.9 | $661.8 | $346.2 |
| Income (for common shares) | $593.4 | $585.9 | $661.8 | $346.2 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $111.3 | $115.3 | $137 | |
| Operating activities | ||||
| Depreciation | $38.9 | $35.6 | $35.9 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.3 | $5 | $1.4 | |
| Total cash flows from operations | $165 | $118.2 | $239.1 | |
| Investing activities | ||||
| Capital expenditures | -$100.2 | -$90.6 | -$108.7 | |
| Investments | ||||
| Total cash flows from investing | -$273.9 | -$101.2 | -$90.6 | -$108.8 |
| Financing activities | ||||
| Dividends paid | -$43.8 | -$14.6 | -$14.7 | -$14.8 |
| Sale and purchase of stock | -$182.1 | -$257.6 | -$175.8 | |
| Net borrowings | -$23.4 | -$0.6 | -$0.6 | |
| Total cash flows from financing | -$553.7 | -$218.3 | -$271 | -$189.5 |
| Effect of exchange rate | $1.3 | -$1.1 | -$8.7 | $14.5 |
| Change in cash and equivalents | -$363 | -$155.6 | -$252.1 | -$44.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $593.4 | $585.9 | $661.8 | $346.2 |
| Operating activities | ||||
| Depreciation | $137.3 | $120.6 | $122.3 | $109.1 |
| Business acquisitions & disposals | -$2.2 | |||
| Stock-based compensation | $23.3 | $23.7 | $37.5 | $34 |
| Total cash flows from operations | $776.5 | $724 | $584 | $472.5 |
| Investing activities | ||||
| Capital expenditures | -$362 | -$284.6 | -$253.4 | -$174.4 |
| Investments | ||||
| Total cash flows from investing | -$368.7 | -$288.2 | -$253.1 | -$179.5 |
| Financing activities | ||||
| Dividends paid | -$57 | -$54.1 | -$51.1 | -$48.1 |
| Sale and purchase of stock | -$407.3 | -$201.3 | -$122.5 | -$93.1 |
| Net borrowings | -$2.3 | -$45.5 | -$2.2 | -$2.3 |
| Total cash flows from financing | -$459.6 | -$293.6 | -$168.1 | -$137.1 |
| Effect of exchange rate | $11.4 | -$10.5 | -$15.7 | $20.5 |
| Change in cash and equivalents | -$40.4 | $131.7 | $147.1 | $176.4 |
News
Fundamentals
| Market cap | $19.76B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 72.50M |
| Revenue | $2.88B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $499.60M |
| Revenue Q/Q | -0.07% |
| Revenue Y/Y | -1.71% |
| P/E ratio | 39.55 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 6.87 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $6.89 |
|---|---|
| ROA | 13.69% |
| ROE | N/A |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.00 |
| Quick ratio | 2.23 |